Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 3/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3829027 | 0.91 | NR3C2 (0.39) | NR3C2MMP12KCNH2MGLLMAPT | |
| SCHEMBL16460174 | 0.84 | MMP12 (0.38) | NR3C2MMP12KCNH2CYP11B1CYP11B2 | |
| SCHEMBL13424716 | 0.81 | MMP12 (0.43) | NR3C2MMP12MAPTPARP1KMT2A | |
| SCHEMBL2768693 | 0.79 | NR3C2 (0.38) | NR3C2MMP12KCNH2MGLLMAPT | |
| SCHEMBL13356483 | 0.78 | KCNH2 (0.38) | NR3C2MMP12KCNH2MGLLMAPT | |
| SCHEMBL15979052 | 0.78 | KCNH2 (0.43) | NR3C2MMP12KCNH2MGLLMAPT | |
| SCHEMBL592791 | 0.72 | NR3C2 (0.47) | NR3C2MMP12KCNH2MAPTALDH1A1 | |
| SCHEMBL29712026 | 0.72 | NR3C2 (0.47) | NR3C2MMP12KCNH2MAPTALDH1A1 | |
| SCHEMBL3262979 | 0.72 | NR3C2 (0.47) | NR3C2MMP12KCNH2MGLLMAPT | |
| SCHEMBL3243927 | 0.72 | ALDH1A1 (0.44) | NR3C2MAPTALDH1A1PARP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2181996-A1 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2010-05-05 | — | — | EP | disclosed |
| US-7691850-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| EP-1784410-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2009-07-15 | — | — | EP | disclosed |
| US-20080194547-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| US-7312212-B2 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2007-12-25 | — | — | US | disclosed |
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | SMITHKLINE BEECHAM CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070254872-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| US-20070161627-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2007-07-12 | — | — | US | disclosed |
| EP-1784410-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-05-16 | — | — | EP | disclosed |
| EP-1773831-A1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006020561-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006014580-A1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-02-09 | — | — | WO | disclosed |
| US-20050159411-A1 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | NPM1, TOP1, HMGB1 | NR3C2 632/4885MMP12 983/4885KCNH2 3440/4885 |
| US-20070161627-A1 | Antibacterial agents | NQO2, NQO1, NDUFV2 | NR3C2 4033/4885MMP12 1278/4885KCNH2 2586/4885 |
| US-20070254872-A1 | Antibacterial Agents | NQO2, NQO1, NDUFV2 | NR3C2 4033/4885MMP12 1278/4885KCNH2 2586/4885 |
| US-20050159411-A1 | Aminopiperidine derivatives | AMPD2, AMPD3, NPEPPS | NR3C2 4458/4885MMP12 2523/4885KCNH2 1182/4885 |
| US-20080194547-A1 | Antibacterial Agents | NQO2, NQO1, NDUFV2 | NR3C2 3744/4885MMP12 1558/4885KCNH2 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.